Insider Buying: Cooper Companies (NASDAQ:COO) Director Acquires $539,100.00 in Stock

The Cooper Companies, Inc. (NASDAQ:COO) Director Lawrence Kurzius purchased 10,000 shares of the stock in a transaction on Monday, September 14th. The shares were purchased at an average cost of $53.91 per share, with a total value of $539,100.00. Following the transaction, the director owned 21,099 shares of the company’s stock, valued at $1,137,447.09. This trade represents a 90.10% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Lawrence Erik Kurzius also recently made the following trade(s):

• On Wednesday, September 16th, Lawrence Kurzius acquired 10,000 shares of Cooper Companies stock. The stock was purchased at an average price of $54.93 per share, for a total transaction of $549,300.00.

Cooper Companies Stock Performance

NASDAQ COO opened at $53.78 on Friday. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.22 and a quick ratio of 0.73. The Cooper Companies, Inc. has a 1-year low of $51.01 and a 1-year high of $89.83. The firm has a market capitalization of $10.23 billion, a P/E ratio of 18.35, a P/E/G ratio of 2.22 and a beta of 0.82. The business’s 50-day simple moving average is $70.23 and its 200-day simple moving average is $68.77.

Cooper Companies (NASDAQ:COO) last posted its earnings results on Wednesday, September 9th. The medical device company reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.12 by $0.03. The firm had revenue of $1.07 billion during the quarter, compared to the consensus estimate of $1.10 billion. Cooper Companies had a net margin of 13.46% and a return on equity of 10.90%. The company’s revenue was up .5% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.49 EPS. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. Equities analysts predict that The Cooper Companies, Inc. will post 4.53 EPS for the current year.

Cooper Companies declared that its board has authorized a stock buyback plan on Wednesday, September 9th that allows the company to buyback $3.00 billion in outstanding shares. This buyback authorization allows the medical device company to reacquire up to 22.7% of its stock through open market purchases. Stock buyback plans are generally a sign that the company’s management believes its stock is undervalued.

Wall Street Analyst Weigh In

COO has been the topic of several research reports. Wall Street Zen lowered Cooper Companies from a “buy” rating to a “hold” rating in a research report on Saturday, September 12th. Stifel Nicolaus set a $70.00 target price on Cooper Companies and gave the stock a “buy” rating in a research report on Thursday, September 10th. Mizuho set a $75.00 target price on Cooper Companies and gave the company an “outperform” rating in a research note on Thursday, September 10th. UBS Group lowered their target price on Cooper Companies from $75.00 to $66.00 and set a “neutral” rating for the company in a research note on Thursday, September 10th. Finally, KeyCorp reiterated a “sector weight” rating on shares of Cooper Companies in a report on Friday, June 5th. Five research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $71.47.

Cooper Companies News Roundup

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Director Lawrence Kurzius purchased 10,000 shares for approximately $549,300, increasing his position by 47.4%. Other directors, including Paul Keel and Walter Rosebrough Jr., also recently bought shares. The purchases may provide a modest confidence signal from insiders after the selloff. Insider purchase report
• Neutral Sentiment: Jana Partners is pressing Cooper to replace its chief executive and pursue an urgent overhaul, citing “chronic underperformance.” The activist campaign could create a catalyst for strategic change, but it also increases leadership and execution uncertainty. Wall Street Journal activist report
• Negative Sentiment: Cooper’s latest quarterly results beat adjusted EPS expectations, $1.15 versus $1.12, but revenue of approximately $1.07 billion missed the $1.10 billion consensus. Management also reduced fiscal 2026 adjusted EPS guidance to $4.51–$4.55 and revenue guidance to $4.23–$4.25 billion, reflecting weaker contact-lens demand.
• Negative Sentiment: Reports that U.S. distributors are reducing channel inventories have raised concerns about near-term sales and whether the weakness reflects temporary destocking or softer underlying demand. Inventory destocking report
• Negative Sentiment: Pomerantz, Bragar Eagel & Squire, and Levi & Korsinsky announced investigations into potential securities claims. These notices do not establish wrongdoing, but they add legal and headline risk. Analysts have also lowered their consensus price target to about $72.27. Pomerantz investigation

Hedge Funds Weigh In On Cooper Companies

Institutional investors have recently made changes to their positions in the business. BlackRock Inc. bought a new stake in Cooper Companies in the 2nd quarter valued at about $1,077,762,000. Generation Investment Management LLP bought a new position in Cooper Companies in the 2nd quarter worth about $356,304,000. Jupiter Topco LLC acquired a new stake in shares of Cooper Companies in the second quarter valued at approximately $305,074,000. Franklin Resources Inc. increased its stake in shares of Cooper Companies by 108.2% in the fourth quarter. Franklin Resources Inc. now owns 4,022,033 shares of the medical device company’s stock valued at $329,646,000 after purchasing an additional 2,089,763 shares during the period. Finally, JANA Partners Management LP raised its holdings in shares of Cooper Companies by 0.5% during the second quarter. JANA Partners Management LP now owns 3,582,480 shares of the medical device company’s stock valued at $256,900,000 after buying an additional 17,322 shares during the last quarter. 24.39% of the stock is owned by institutional investors and hedge funds.

Cooper Companies Company Profile

Cooper Companies, Inc is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company develops, manufactures and markets products through two primary business segments: CooperVision and CooperSurgical.

CooperVision specializes in contact lenses, including daily disposable, toric, multifocal, multifocal toric, specialty and myopia-management lenses. Its products are designed to address a range of vision-correction needs, including astigmatism, presbyopia and irregular corneas.